Elutia Q3 revenue $3.3M, closes $88M BioEnvelope sale to Boston Scientific, pays off debt

ELUTIA INC.

Net sales $3.3M (down from $3.7M YoY); loss from operations $5.2M vs $9.2M loss a year ago.
Closed sale of BioEnvelope business to Boston Scientific for $88M; used $27.8M to repay SWK loan facility in full.
Advancing NXT-41x for plastic/reconstructive surgery; FDA clearance of base matrix expected 2H26, drug-eluting version 1H27.
Cash balance $4.7M at Sep 30, 2025; received $80.3M net proceeds on Oct 1, 2025 after closing and escrow.
Settled 7 additional FiberCel cases, leaving only 6 unresolved; Guido J. Neels appointed to Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.